Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | intermediate filament protein | 0.003 | 0.4263 | 0.4263 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0051 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.4263 | 0.4263 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0051 | 1 | 1 |
Onchocerca volvulus | 0.003 | 0.4263 | 0.5 | |
Loa Loa (eye worm) | intermediate filament protein | 0.003 | 0.4263 | 0.4263 |
Onchocerca volvulus | 0.003 | 0.4263 | 0.5 | |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.003 | 0.4263 | 0.4263 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0051 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.003 | 0.4263 | 0.4001 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0051 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.003 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0051 | 1 | 1 |
Brugia malayi | intermediate filament protein | 0.003 | 0.4263 | 0.4001 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 1 | 1 |
Echinococcus granulosus | lamin | 0.003 | 0.4263 | 0.4263 |
Echinococcus multilocularis | lamin | 0.003 | 0.4263 | 0.4263 |
Echinococcus granulosus | lamin dm0 | 0.003 | 0.4263 | 0.4263 |
Echinococcus multilocularis | musashi | 0.003 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0016 | 0.0438 | 0.0438 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.4113 | 0.4113 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 1.38 uM | Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after 6 hrs | ChEMBL. | 20346666 |
IC50 (functional) | = 1.38 uM | Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after 6 hrs by immunoassay | ChEMBL. | 20637613 |
Inhibition (functional) | = 45 % | Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha production at 20 mg/kg, po administered 30 mins before LPS challenge measured after 1 hr by ELISA | ChEMBL. | 20346666 |
Inhibition (functional) | = 45 % | Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha production at 20 mg/kg, po administered 30 mins before LPS challenge measured after 1 hr by ELISA | ChEMBL. | 20637613 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 20346666 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.